论文部分内容阅读
目的检测卵巢癌细胞株及紫杉醇化疗后卵巢癌组织中WNT-1及FZD-1基因蛋白表达的变化及其意义。方法选用卵巢癌紫杉醇耐药细胞株SKOV3/TAX及敏感细胞株SKOV3,及58例卵巢癌组织,包括术后紫杉醇化疗后复发患者19例(化疗组),术前未化疗患者39例(未化疗组)。采用免疫组化二步法,检测卵巢癌组织及细胞中WNT-1及FZD-1基因的蛋白表达。结果 1.卵巢癌组织中:化疗组WNT-1及FZD-1的蛋白表达光密度值较未化疗组明显降低(分别为30931.34±16420.04 vs 45917.65±12015.39;38625.20±19689.97 vs 55585.82±26330.13),以上差异均有统计学意义(P<0.05);光镜下观察耐药细胞株中WNT-1及FZD-1蛋白表达强度均明显低于敏感株;2.化疗组WNT-1蛋白表达在子宫内膜样腺癌中明显低于浆乳癌(19215.88±6506.49 vs 43193.53±16803.05,P=0.014);未化疗组各基因蛋白表达在年龄、临床分期,分化程度和病理类型中均无显著性差异。3.总体上FZD-1与WNT-1蛋白表达呈显著正相关(r=0.479,P=0.000),化疗组及未化疗组中WNT-1与FZD-1蛋白表达也均呈正相关(分别为r=0.551、P=0.015;r=0.345、P=0.032)。结论 WNT-1、FZD-1基因蛋白表达下调可能与卵巢癌紫杉醇化疗耐药有一定相关性。
Objective To detect the changes of Wnt-1 and FZD-1 protein expression in ovarian cancer cell lines and paclitaxel-treated ovarian cancer tissues and their significance. Methods The ovarian cancer cell line SKOV3 / SKX3 and SKOV3 / SKOV3 cell line were selected, and 58 cases of ovarian cancer were selected, including 19 cases of postoperative chemotherapy with paclitaxel (chemotherapy group), 39 cases of chemotherapy without chemotherapy group). The immunohistochemical two-step method was used to detect the protein expression of WNT-1 and FZD-1 in ovarian cancer tissues and cells. In ovarian cancer, the protein expression of WNT-1 and FZD-1 in the chemotherapy group was significantly lower than that in the non-chemotherapy group (30931.34 ± 16420.04 vs 45917.65 ± 12015.39; 38625.20 ± 19689.97 vs 55585.82 ± 26330.13 respectively) (P <0.05). The expression of WNT-1 and FZD-1 protein in the resistant cell lines was significantly lower than that of the susceptible cells under the light microscope.2. The expression of WNT-1 protein in the chemotherapy group was significantly higher in the uterus Mesenteric adenocarcinoma was significantly lower than that of primary breast cancer (19215.88 ± 6506.49 vs 43193.53 ± 16803.05, P = 0.014). There was no significant difference in age, clinical stage, differentiation and pathological type between the two groups. There was a significant positive correlation between the expression of FZD-1 and WNT-1 protein (r = 0.479, P = 0.000). There was also a positive correlation between WNT-1 and FZD-1 protein expression in chemotherapy group and non-chemotherapy group r = 0.551, P = 0.015; r = 0.345, P = 0.032). Conclusion The down-regulation of WNT-1 and FZD-1 protein expression may be related to the chemoresistance of paclitaxel in ovarian cancer.